Compare Icl Group Ltd (ICL) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Icl Group Ltd vs Medtronic PLC — how do they compare? Icl Group Ltd trades at $5.46 (market cap $6.94B), while Medtronic PLC trades at $89.13 (market cap $116.07B). The key difference: Medtronic PLC is far larger — about 16.7× Icl Group Ltd's market cap, and Icl Group Ltd pays the higher dividend (3.86%). Which is the better fit depends on your goals.
| ICL | MDT | |
|---|---|---|
Market Cap | $6.94B | $116.07B |
Sector | Basic Materials | Health |
52-Week High | $6.84 | $105.35 |
52-Week Low | $4.80 | $73.75 |
Enterprise Value | $9.58B | $134.82B |
Dividend Yield | 3.86% | 3.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICL trades at $5.34, up 0.56% today, with a bullish technical signal supported by moving averages. Recent Q2 2026 earnings beat expectations with EPS of $0.12 versus $0.11 expected, continuing a trend of positive surprises. The company maintains stable cash flow from operations around $1.1B annually and pays consistent dividends, with recent payments of $0.05 and $0.06 per share.
Outlook remains cautious with 100% analyst hold ratings citing fair valuation. Risks include declining profit margins (3.95% net margin in 2025) and exposure to commodity price volatility. The stock offers moderate value with P/E of 22.25 and P/S of 0.89, but requires monitoring of cost transformation program effectiveness amid raw material inflation.
Medtronic (MDT) trades at $89.41, up 2.58% on the day, reflecting positive momentum. The stock exhibits bullish technical signals with strong moving average support and a consensus analyst price target of $98.75. Fundamentally, the company reported revenue of $33.54B for 2025 with a net income margin of 13.2%, and has consistently beaten EPS estimates in recent quarters. Recent news highlights institutional acquisitions and positive developments in medical technology platforms.
The outlook for MDT is positive, driven by earnings beats, robust cash flow, and growth in cardiac and robotic surgery segments. Key opportunities include undervaluation relative to analyst targets and dividend stability. Risks involve rising debt levels and competitive pressures in the medtech sector. The stock presents a compelling case for growth-oriented income investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
